Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Identifying early symptoms of choroidal neovascularisation in second eyes of patients with unilateral wet age related macular degeneration using a telephone evaluation method



Patients undergoing intravitreal injections for nAMD are often anxious about early detection of nAMD in their fellow eyes. The purpose of this study was to evaluate a home-based telephone method for helping patients to monitor for symptoms of second eye involvement.


Using a five-staged evaluation tool, telephone-assisted evaluations were repeatedly performed on the patients’ fellow eyes every 4 weeks for 1 year. A decision on presence or absence of nAMD was made after each telephone evaluation. Slitlamp examination and OCT scan were performed at 3, 6, 9 and 12 months or whenever nAMD was suspected from the telephone evaluation. The sensitivity and specificity values were calculated from the true and false positive and negative rates of each of the five composite stages.


In total, 514 telephone episodes comprising 2570 evaluations were conducted on fellow eyes of 50 patients over one year. Three patients (6%) developed nAMD in fellow eyes. The sensitivity of all of the stages was low (33.3%). The specificity of the five stages ranged from 91.3% to 98.6%. The highest specificity was achieved by the near acuity component of the tool.


We were unable to demonstrate a high sensitivity for the five-staged tool but the near acuity component of this tool had a very high specificity. This could have potential for “ruling out” nAMD and reducing the burden of false positive episodes for a large group of patients who are at risk of developing nAMD in their second eyes.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Example of modified A4 Bailey-Lovie Chart.
Fig. 2: OCT showing development of CNV.


  1. Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313.

    CAS  Article  Google Scholar 

  2. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209–13.e2.

    Article  Google Scholar 

  3. Belkin M, Kalter-Leibovici O, Chetrit A, Skaat A. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2013;155:404.

    Article  Google Scholar 

  4. Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PloS One. 2014;9:e101072.

    Article  Google Scholar 

  5. Bressler NM, Doan QV, Varma R, Lee PP, Suner IJ, Dolan C, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129:709–17.

    Article  Google Scholar 

  6. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Seven-Up Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

    Article  Google Scholar 

  7. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893–900.

    CAS  Article  Google Scholar 

  8. Rovner BW, Casten RJ. Activity loss and depression in age-related macular degeneration. Am J Geriatr Psychiatry. 2002;10:305–10.

    Article  Google Scholar 

  9. Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, et al. Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:2035–41.

    Article  Google Scholar 

  10. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26.

    Article  Google Scholar 

  11. Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121:1966–75.

    Article  Google Scholar 

  12. Cornish EE, Teo KY, Nguyen V, Squirrel D, Young S, Gillies MC et al. Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project. Retina 2020. [E-pub ahead of print]

  13. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthal. 2007;144:850–7.

    CAS  Article  Google Scholar 

  14. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.

    Article  Google Scholar 

  15. Canan H, Sızmaz S, Altan-Yaycıoğlu R, Sarıtürk Ç, Yılmaz G. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. Clin Interv Aging. 2014;9:141–5.

    Article  Google Scholar 

  16. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122–9.

    Article  Google Scholar 

  17. Uchida A, Manjunath D, Singh RP, Rachitskaya AV, Kaiser PK, Srivastava SK, et al. Optical coherence tomography angiography in eyes with indeterminate choroidal neovascularization: results from the AVATAR Study. Ophthalmol Retin. 2018;2:1107–17.

    Article  Google Scholar 

  18. Bailey ST, Thaware O, Wang J, Hagag AM, Zhang X, Flaxel CJ, et al. Detection of nonexudative choroidal neovascularization and progression to exudative choroidal neovascularization using oct angiography. Ophthalmol Retin. 2019;3:629–36.

    Article  Google Scholar 

  19. Wong TY, Lanzetta P, Bandello F, Eldem B, Navarro R, Lövestam-Adrian M, et al. Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration: an expert panel consensus. Retina. 2020;40:599.

    Article  Google Scholar 

  20. Crossland M, Rubin G. The Amsler chart: absence of evidence is not evidence of absence. Br J Ophthalmol. 2007;91:391–3.

    Article  Google Scholar 

  21. Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014;121:535–44.

    Article  Google Scholar 

  22. Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina. 2013;33:1863–70.

    Article  Google Scholar 

  23. Keane PA, De Salvo G, Sim DA, Goverdhan S, Agrawal R, Tufail A. Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clin Ophthalmol. 2015;9:353–66.

    Article  Google Scholar 

  24. Schwartz R, Loewenstein A. Early detection of age related macular degeneration: current status. Int J Retin Vitreous. 2015;1:1–8.

    Article  Google Scholar 

  25. Bujang MA, Adnan TH. Requirements for minimum sample size for sensitivity and specificity analysis. J Clin diagnostic Res. 2016;10:YE01–YE06.

    Google Scholar 

  26. Whillans J, Nazroo J. Assessment of visual impairment: the relationship between self-reported vision and ‘gold-standard’measured visual acuity. Br J Vis Impairment. 2014;32:236–48.

    Article  Google Scholar 

  27. Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Continuing Educ Anaesth Crit Care Pain. 2008;8:221–3.

    Article  Google Scholar 

Download references



Funded in part by the Tripartite grant from three charitable bodies South Staffordshire Medical FoundationReg. Charity No: 1075209 Rotha Abraham Bequest Reg. Charity No: 509234 The Royal Wolverhampton Hospitals NHS Trust Charity Reg. Charity No: 1059467.

Author information

Authors and Affiliations


Corresponding author

Correspondence to William Fusi-Rubiano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fusi-Rubiano, W., Webb, R., Narendran, N. et al. Identifying early symptoms of choroidal neovascularisation in second eyes of patients with unilateral wet age related macular degeneration using a telephone evaluation method. Eye 35, 3028–3034 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links